Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04223752 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT04223752 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 41 participants.
The verdict
NCT04223752, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP).
Interventions
- DRUG Ceftolozane/Tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2020-04-17 |
| Est. Completion | 2024-09-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04223752
The ClinicalTrials.gov registry entry for NCT04223752 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ceftolozane/Tazobactam is the first listed.
NCT04223752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04223752 about?
NCT04223752 is a clinical study titled "Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)". This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP).
What is the current status of trial NCT04223752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2020-04-17. Estimated completion is 2024-09-14.
What interventions are being tested in trial NCT04223752?
The interventions under investigation include: Ceftolozane/Tazobactam (DRUG).
Who is sponsoring clinical trial NCT04223752?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.